Novo Nordisk’s senior vice president of US operations Dave Moore discusses the producer’s newly launched once-a-day oral weight loss pill on ‘The Claman Countdown.’
Novo Nordisk on Tuesday announced plans to reduce the price of popular drugs for diabetes and weight loss Ozempic and Wegovy up to 50% in the US next year.
The Danish drugmaker revealed that the price cut will take effect on Jan. 1, 2027, and the timing will coincide with new, lower prices for Ozempic and Wegovy under Medicare plans for American adults.
The company’s announcement shows that the price of a range of doses of its drugs Ozempic and Wegovy will be reduced to $675, representing a 50% price reduction for Wegovy and 35% for Ozempic from the current level. The price reduction also applies to Wegovy and Rybelsus tablets.
“The Wegovy and Ozempic list price reductions are the best way to address an unprecedented opportunity to help the more than 100 million people with obesity and the more than 35 million people with type 2 diabetes in the United States,” said Jamey Millar, VP of US operations. Novo Nordisk.
BIG NOVO NORDISK REPORTS HIGHEST INTEREST FOR ONCE-DAILY, ORAL LOSS PILL.
Novo Nordisk has announced that it will reduce the prices of Wegovy and Ozempic by up to 50% from next year. (Dhiraj Singh/Bloomberg via Getty Images)
“Our actions today answer that call and remove cost barriers so that the value of Wegovy and Ozempic can be seen by more patients,” he explained.
“The lower list price is intended to connect more people to our new medicines, especially those with new medicines out-of-pocket expenses are linked to price lists, such as people with high-deductible health plans or co-insurance benefit plans,” added Millar.
AIRLINES HAVE 580 MILLION REASONS TO LIKE GLP-1 HEAVY DUTY DRUGS, GET ANALYSIS
| A ticker | Security | Finally | Change | Change % |
|---|---|---|---|---|
| An NGO | NOVO NORDISK A/S | 39.63 | -7.79 |
-16.43% |
Novo Nordisk’s GLP-1 drugs contain semaglutide as an active ingredient, which has received FDA approval as a therapeutic drug. adults with obesity in the case of Wegovy, while Ozempic is approved for type 2 diabetes.
Additionally, Ozempic injections are FDA approved for type 2 diabetes and chronic kidney disease, while both Wegovy and Ozempic are comorbid approved. heart disease.
Price changes do not affect direct-to-patient or consumer prices.
SOON COSTCO MEMBERS WILL HAVE ACCESS TO WEIGHT SUPPORT SHOTS AT A BIG DISCOUNT
Wegovy and other GLP-1 drugs are used to reduce weight and treat diabetes. (Shelby Knowles/Bloomberg via Getty Images)
The market for GLP-1 drugs has become increasingly competitive and the shift to consumer-driven, cash-based channels makes price points more sensitive. Novo Nordisk sells Wegovy on its direct-to-consumer website for $349, about one-third of its official list price.
Both Novo Nordisk and its leading competitor, Eli Lilly, signed deals with the US government this year to lower prices and sell products. TrumpRx.gov – a website that directs consumers to company websites that are direct to consumers.
GET FOX BUSINESS ON THE GO BY CLICKING HERE
The two companies face competition from cheaper compounded forms of medicine offered by social networks such as Hims & Hers, which are allowed to make and sell medicines in personalized doses or formulations.
Reuters contributed to this report.
